About Tivic Health


About Tivic Health

Headquarters:  San Francisco Bay Area, CA
Sector:  Healthtech, Bioelectronic Medicine
Stage:  Commercial

Tivic Health Systems, Inc. is a commercial-stage bioelectronic medicine company focused on treating diseases and conditions by modulating the electrical signals carried along various nerve pathways. We focus on non-invasive products that offer consumers choice in the treatment of inflammation and related conditions.

Our first FDA-approved product, ClearUP® Sinus Pain Relief (“ClearUP”), is a patented handheld device that uses gentle pulsed electron waves to relieve symptoms of sinus and nasal inflammation, nasal allergies, sinus infections, chronic sinusitis, cold and flu.

Roughly 200 million people in the U.S. are impacted by these conditions, representing a potential $8 billion U.S. market.

ClearUP offers a convenient, non-drug alternative for sinus health and is available on Amazon, Best Buy, Walgreens, Walmart and other major e-commerce websites.

ClearUP is built on our non-invasive bioelectronic platform, combining an ergonomic form factor, programmable hardware and patented algorithms that personalize and optimize treatment. This platform is covered by 4 issued U.S. patents. Additionally, 18 patents are pending.

We continue to conduct research to apply this platform to deliver evidence-based bioelectronic alternatives for additional diseases and conditions.

McKinsey & Company estimates that bioelectronic medicine “represents a multibillion dollar opportunity even with modest penetration.”

Play Video

Users and doctors share their experiences with ClearUP

Key Milestones

  • 2016 Q3: Tivic Health was founded
  • 2018 Q2: Completed FDA pivotal trial for ClearUP
  • 2018 Q3: Received FDA 510(k) for ClearUP
  • 2019 Q1: Received FDA’s first clearance for ClearUP
  • 2019 Q3: ClearUP began commercial shipment
  • 2019 Q4: Received ISO 13485 certification
  • 2020 Q1: ClearUP received CE Mark approval
  • 2020 Q3: USPTO granted Tivic’s first patents
  • 2021 Q1: Received FDA’s second clearance for ClearUP
  • 2021 Q2: Over 20,000 lives touched by ClearUP
  • 2021 Q2: Bridge financing closed bringing investment to date $13 million
  • 2021 Q3: Tivic Health set terms for a $17 million IPO
  • 2021 Q4: Tivic Health (“TIVC”) listed on NASDAQ in November
  • 2022 Q1: ClearUP named best sinus pain relief by Global Health & Pharma Magazine
  • 2022 Q2: Broaden our IP portfolio claims to 96 and initiated the development of a product candidate in migraine
  • 2022 Q3: Over 35,000 lives touched by ClearUP
  • 2022 Q4: Reduced 40% in cost for ClearUP from initial product

Awards & Recognition






Meet the Tivic Team